Skip to main content

Table 1 Clinical characteristics and outcomes of H1N1(v) critically ill immunocompromised patients

From: Clinical features of H1N1 2009 infection in critically ill immunocompromised patients

Patient Type of immune deficiency Chemotherapy Immuno- suppressive agents Lymphocyte count Time, in days, from respiratory symptoms to ICU admission Ventilatory support Superinfection Anti-infectious agentsa Outcome
1 Chronic myeloid leukemia No No 4,000 3 NIV Clinically documented C3G/macrolide Alive
2 Allogeneic BMT (12 months ago) with GVHD No Yes (steroid/CIs) 800 1 MV Clinically documented Piperacillin/FQ Dead
3 Allogeneic BMT (15 months ago) with GVHD No Yes (steroid/CIs) 600 1 NIV Escherichia coli + Aspergillus fumigatus Imipeneme/FQ Dead
4 Autologous BMT for multiple myeloma Yes Yes (steroid) 50 5 None Clinically documented Piperacillin/macrolide Alive
5 Renal transplantation Yes Yes (steroid/CIs/MMF) 1,200 5 MV Pseudomonas aeruginosa Piperacillin/macrolides Dead
6 HIV No No 1,800 3 None Streptococcus pneumoniae C3G/macrolide Alive
7 Autologous BMT for multiple myeloma Yes Yes (steroid) 100 5 MV Clinically documented Piperacillin/macrolide Alive
8 Myelodysplasia Yes Yes (steroid) 2,000 3 MV E. coli Piperacillin/macrolide Dead
9 Mantle cell lymphoma No No 100 2 NIV and MV S. pneumoniae C3G/macrolide Alive
10 Solid organ transplantation No Yes (steroid) 2,000 2 None S. pneumoniae C3G/macrolide Alive
  1. aAll patients were receiving oseltamivir. BMT, bone marrow transplantation; C3G, third-generation cephalosporin; CI, calcineurin inhibitor; FQ, fluoroquinolone; GVHD, graft-versus-host disease; ICU, intensive care unit; MMF, mycophenolate mofetil; MV, mechanical ventilation; NIV, non-invasive mechanical ventilation.